ArticleJournal of veterinary internal medicine2026
Serum peptidomic profiling identifies systemic JAK-STAT and PI3K-Akt pathway dysregulation in cats with chronic gingivostomatitis.
Article in Journal of veterinary internal medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundChronic gingivostomatitis in cats is a debilitating inflammatory disease marked by severe oral pain and systemic immune dysregulation. Although localized oral pathology is well-documented, the systemic peptidomic profile remains largely unclear. HYPOTHESIS/
objectivesCharacterize the serum peptidomic profiles of cats with feline chronic gingivostomatitis (FCGS) and identify systemic biomarkers and signaling hubs that drive disease pathogenesis and therapeutic interactions. ANIMALS: Client-owned cats with clinically and histopathologically confirmed FCGS (n = 34) and healthy controls (n = 18).
methodsA case-control, cross-sectional study was conducted. All cats were screened for feline leukemia virus, feline immunodeficiency virus, and feline heartworm infections. Serum samples were analyzed using matrix-assisted laser desorption/ionization-time-of-flight mass spectrometry (MALDI-TOF MS) to produce peptide mass fingerprints. Detailed peptide identification was conducted using nanoscale liquid chromatography-tandem mass spectrometry (nano LC-MS/MS). Functional enrichment and protein-protein/chemical interaction networks were developed using ShinyGO and the Kyoto Encyclopedia of Genes and Genomes database.
resultsBoth MALDI-TOF MS and nano LC-MS/MS identified distinct systemic protein signatures that distinguished FCGS from controls. Fifteen proteins showed significant changes, with 13 increased (including inflammatory markers such as interleukin (IL)-6 and interferon-γ) and 2 decreased (gastrin, IL-18). Network analysis identified 8 key proteins (eg, p21(CDKN1A), CASP1, IL-6) that interact with FCGS drug treatments. These systemic changes focus on the Janus kinase-signal transducers and activators of transcription (JAK-STAT) and phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT; PI3K-Akt) pathways, which are important therapeutic targets. CONCLUSIONS AND CLINICAL IMPORTANCE: Our study provides a molecular framework for FCGS. Whereas MALDI-TOF MS enables rapid systemic profiling, nano LC-MS/MS identifies key dysregulated pathways, specifically IL-6/JAK-STAT and PI3K-Akt. These findings offer potential therapeutic targets and a basis for monitoring molecular pathology in affected cats.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.